NFT
BCAX

Nan Fung Trinity’s Bicara Therapeutics BCAX Stock Holding History

Nan Fung Trinity’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7M Hold
427,885
– – 1.25% 32
2026
Q1 		$8.51M Buy
427,885
+55,500
+15% +$955K 0.93% 41
2025
Q4 		$6.27M Sell
372,385
-12,500
-3% -$213K 0.5% 59
2025
Q3 		$6.08M Buy
384,885
+42,000
+12% +$470K 0.61% 50
2025
Q2 		$3.19M Buy
+342,885
New +$4.09M 0.38% 51

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nan Fung Trinity's BCAX Position: Q2 2026 in Review

Nan Fung Trinity held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 427,885 shares worth $12.7M. The position accounts for 1.25% of the portfolio, ranked #32.

Nan Fung Trinity first reported a position in BCAX in Q2 2025 and has held it in 5 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Nan Fung Trinity held 427,885 shares of Bicara Therapeutics worth $12.7M as of Q2 2026.
  • Nan Fung Trinity left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up 1.25% of Nan Fung Trinity's portfolio in Q2 2026, its #32 holding.
  • Nan Fung Trinity first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Nan Fung Trinity's 13F filing for Q2 2026, filed 24 Jul 2026.